Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of avosentan in diabetic kidney disease
2008-000786-32Phase 2Completed
- Sponsor
- Speedel
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Avosentan dose-ranging with Placebo (2 arms). Primary endpoint: Relative change in albumin-creatinine ratio from baseline to Week 12. Started May 2008; status: completed.
02
Drugs
avorsentan
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-000786-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000786-32.